Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome.
This consensus document reviews the current status of the epidemiology, social impact, patient quality of life, pathophysiology, diagnosis and treatment of irritable bowel syndrome. Current evidence suggests that two major mechanisms may interact in irritable bowel syndrome: altered gastrointestinal motility and increased sensitivity of the intestine. However, other factors, such as psychosocial factors, intake of food and prior infection, may contribute to its development. Management of patients is based on a positive diagnosis of the symptom complex, careful history and physical examination to exclude 'red flags' as risk factors for organic disease, and, if indicated, investigations to exclude other disorders. Therapeutic choices include dietary fibre for constipation, opioid agents for diarrhoea and low-dose antidepressants or infrequent use of antispasmodics for pain, although the evidence basis for efficacy is limited or in some cases absent. Psychotherapy and hypnotherapy are the subject of ongoing study. Treatment should be tailored to patient needs and fears. Novel therapies are emerging, and drugs acting on serotonin receptors have proven efficacy and a scientific rationale and, if approved, should be useful in the overall management of patients with irritable bowel syndrome. Patient and physician education, early identification of psychosocial issues and better therapies are important strategies to reduce the suffering and societal cost of irritable bowel syndrome.
Mayo Clinic, Rochesster, MN 55905, USA. camilleri.michael@mayo.edu
M
M
Camilleri
R C
RC
Heading
W G
WG
Thompson
D000328:Adult; D000368:Aged; D000930:Antidiarrheals / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D017281:Cost of Illness; D004043:Dietary Fiber / Q000627:therapeutic use; D005260:Female; D005769:Gastrointestinal Motility; D006801:Humans; D008297:Male; D008875:Middle Aged; D011619:Psychotropic Drugs / Q000627:therapeutic use; D011788:Quality of Life; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
D000930:Antidiarrheals; D004043:Dietary Fiber; D011619:Psychotropic Drugs; D017366:Serotonin Receptor Agonists